Zhejiang Ausun Pharmaceutical News

Aoxiang Pharmaceutical (603229): Stable main business, R&D, strengthening competitiveness, optimistic about follow-up formulation space

Aug 25 00:00

Aoxiang Pharmaceutical (603229): Q2 performance was slightly lower than market expectations, and the share of high-profit products increased

Aug 24 00:00

Aoxiang Pharmaceutical (603229): APIs and CXO business growth steady growth formulations create a third growth curve

Jul 31 00:00

Aoxiang Pharmaceutical (603229): Achieving relatively rapid growth under a high base of 24Q1, the development of specialty APIs and formulations accelerates development

Jun 4 15:41

Aoxiang Pharmaceutical (603229): Production capacity releases energy, boosts API growth

Apr 27 00:00

Aoxiang Pharmaceutical (603229): Performance meets expectations, and new high-profit varieties continue to drive growth

Oct 30, 2023 00:00

Aoxiang Pharmaceutical (603229): Maintaining a high level of profitability, formulations are expected to open up more space in the future

Oct 28, 2023 00:00

Aoxiang Pharmaceutical (603229): Steady increase in gross margin around high technical difficulty and time window

Oct 28, 2023 00:00

Aoxiang Pharmaceutical (603229): R&D leads the release of future production capacity and high growth of specialty APIs

國金證券Aug 29, 2023 00:00

Aoxiang Pharmaceutical (603229): R&D drives growth, and the capability circle of specialty API companies continues to expand

國金證券May 30, 2023 00:00

Aoxiang Pharmaceutical (603229): CRO/CDMO drives rapid growth in production capacity and specialty product layout continue to reap

中泰證券Apr 28, 2023 00:00

Aoxiang Pharmaceutical (603229): Performance continues to grow rapidly and is strong after growth

招商證券Jan 18, 2023 00:00

Aoxiang Pharmaceutical (603229): CDMO and superior varieties continue to drive growth, new production capacity, new product growth can be expected

中泰證券Jan 17, 2023 00:00

Aoxiang Pharmaceutical (603229) Review Report for the Third Quarter of 2022: CDMO and Advantage Varieties Continue to Release, Gross Margins Improve

浙商證券Nov 5, 2022 00:00

Aoxiang Pharmaceutical (603229): CDMO and superior varieties drive strong growth in new production capacity, new products poised for development

中泰證券Oct 30, 2022 00:00

Aoxiang Pharmaceutical (603229) 2022 Interim Report Review: Project Structure Optimization and Investment Accelerated

浙商證券Sep 2, 2022 00:00

Aoxiang Pharmaceutical (603229): customers + projects continue to promote capacity construction to break through constraints

招商證券Aug 30, 2022 00:00

Aoxiang Pharmaceutical Industry (603229): the epidemic situation does not change the momentum of strong growth, capacity construction is progressing smoothly.

中泰證券Aug 29, 2022 00:00

Aoxiang Pharmaceutical (603229): technology leads the development, the growth rate at the profit end exceeds that at the income end.

招商證券Apr 20, 2022 00:00

Aoxiang Pharmaceutical (603229): higher-than-expected CRO/CDMO leads to sustained and rapid growth

中泰證券Apr 19, 2022 00:00